Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although thrombosis is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are common, particularly in patients with life-threatening complications. In patients who require transplantation, vascular lesions often recur. The molecular pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate therapies are lacking. METHODS: We used double immunostaining to evaluate pathway activation in the mammalian target of rapamycin complex (mTORC) and the nature of cell proliferation in the vessels of patients with primary or secondary antiphospholipid syndrome nephropathy. We also evaluated autopsy specimens from persons who had catastrophic antiphospholipid syndrome. The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway were evaluated in vitro, and potential pharmacologic inhibitors were also tested in vitro. Finally, we studied the effect of sirolimus in kidney-transplant recipients with the antiphospholipid syndrome. RESULTS: The vascular endothelium of proliferating intrarenal vessels from patients with antiphospholipid syndrome nephropathy showed indications of activation of the mTORC pathway. In cultured vascular endothelial cells, IgG antibodies from patients with the antiphospholipid syndrome stimulated mTORC through the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Patients with antiphospholipid syndrome nephropathy who required transplantation and were receiving sirolimus had no recurrence of vascular lesions and had decreased vascular proliferation on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirolimus. Among 10 patients treated with sirolimus, 7 (70%) had a functioning renal allograft 144 months after transplantation versus 3 of 27 untreated patients (11%). Activation of mTORC was also found in the vessels of autopsy specimens from patients with catastrophic antiphospholipid syndrome. CONCLUSIONS: Our results suggest that the mTORC pathway is involved in the vascular lesions associated with the antiphospholipid syndrome. (Funded by INSERM and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oxidative stress and subsequent mTOR activation occurs in various rheumatic diseases257–259.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [257]
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,543
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
Sousa, J. E., Costa, M. A., Abizaid, A. C., Rensing, B. J., Abizaid, A. S., Tanajura, L. F., Kozuma, K., Van Langenhove, G., Sousa, A. G. M. R., Falotico, R., et al. (2001) · Circulation · doi:10.1161/hc4201.098056 · Cited by 672
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Research works printed but not linked: 1
- Alarcon-Segovia D, 1989, J Rheumatol, 16, 762
Cited by
Items 101–200 of 365
Antiphospholipid syndrome: Diagnosis and management in the obstetric patient
Arslan, E., & Branch, D. W. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.10.001 · Cited by 36
Treatment of antiphospholipid syndrome
Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Menegatti, E., Roccatello, D., & Sciascia, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108597 · Cited by 35
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease
Salter, B., & Crowther, M. A. (2024) · Hematology · doi:10.1182/hematology.2024000544 · Cited by 31
Renal involvement in antiphospholipid syndrome
de Azevedo, F. V. A., Maia, D. G., de Carvalho, J. F., & Rodrigues, C. E. M. (2018) · Rheumatology International · doi:10.1007/s00296-018-4040-2 · Cited by 31
“This is an indication that the (mTORC) pathway plays a role in APS-related vascular lesions, representing a potential therapeutic target [59].”
BackgroundIs there a role for immunosuppression in antiphospholipid syndrome?
Sevim, E., Willis, R., & Erkan, D. (2019) · Hematology · doi:10.1182/hematology.2019000073 · Cited by 33
“Kidney transplant recipients with APS who were treated with sirolimus had better outcomes compared with aPLpositive patients who were not treated with sirolimus (70% and 11% graft survival at a mean follow-up of 144 months, respectively).(34) More recently, a primary APS patient with microvascular disease despite warf…”
BackgroundResultOxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome
Lai, Z., Marchena, I., & Perl, A. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.03.024 · Cited by 32
“In a retrospective study of 10 patients with APS nephropathy, who required renal transplantation and received treatment with rapamycin, also known as sirolimus, 7 of 10 patients (70%) had a functioning allograft 144 months after transplantation versus 3 of 27 patients treated without rapamycin (11%) (26).”
BackgroundResultInfluentialIschemic stroke in young adults
Калашникова, Л. А., & Добрынина, Л. А. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2017117823-12 · Cited by 31
“Механизмы действия аФЛ многообразны и включают активацию эндотелия, моноцитов, тромбоцитов, что ведет к выделению тканевого фактора, активирующего внешний путь свертывания крови; ингибирование фибринолитической системы и системы естественного антикоагулянта протеина С; повышение агрегации тромбоцитов; активацию систем…”
Antiphospholipid syndrome, “the best prophet of the future”
Amengual, O., & Atsumi, T. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1435988 · Cited by 36
Domingues, V., Chock, E. Y., Dufrost, V., Risse, J., Seshan, S. V., Barbhaiya, M., Sartelet, H., Erkan, D., Wahl, D. G., & Zuily, S. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103158 · Cited by 30
Yue, C., Li, G., Wen, Y., Li, X., & Gao, R. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170561 · Cited by 30
“010a ESKD or 50% eGFR decline 3 (18) 3 (8) 0.”
BackgroundAn update on inflammation in antiphospholipid syndrome
Ambati, A., Zuo, Y., & Knight, J. S. (2022) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000926 · Cited by 29
Tang, Z., Shi, H., Chen, C., Teng, J., Dai, J., Ouyang, X., Liu, H., Hu, Q., Cheng, X., Ye, J., et al. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.318978 · Cited by 31
“21 Hollerbach et al 22 reported that mTORC1 (mTOR complex 1) inhibitor–rapamycin prevented platelet activation stimulated by aPLs.”
The Journey of Antiphospholipid Antibodies From Cellular Activation to Antiphospholipid Syndrome
Willis, R., Gonzalez, E. B., & Brasier, A. R. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-014-0485-9 · Cited by 34
Under crossfire: thromboembolic risk in systemic lupus erythematosus
Ramirez, G. A., Efthymiou, M., Isenberg, D. A., & Cohen, H. (2018) · Rheumatology · doi:10.1093/rheumatology/key307 · Cited by 30
Genetics of Antiphospholipid Syndrome
Ortiz‐Fernández, L., & Sawalha, A. H. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0869-y · Cited by 29
Redox Pathogenesis in Rheumatic Diseases
Laniak, O. T., Winans, T., Patel, A., Park, J. S., & Perl, A. (2024) · ACR Open Rheumatology · doi:10.1002/acr2.11668 · Cited by 33
“85 Importantly, mTOR blockade improved the survival of renal transplants in patients with aPL nephropathy.”
BackgroundImmunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?
Mormile, I., Granata, F., Punziano, A., de Paulis, A., & Rossi, F. W. (2021) · Biomedicines · doi:10.3390/biomedicines9020132 · Cited by 28
“[103] reported 37 patients with APS nephropathy leading to kidney transplantation.”
BackgroundInfluentialThrombotic Microangiopathies with Rheumatologic Involvement
Babar, F., & Cohen, S. D. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.06.010 · Cited by 27
Challenging Mimickers of Primary Systemic Vasculitis
Miloslavsky, E. M., Stone, J. H., & Unizony, S. H. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.09.011 · Cited by 28
“The mTORC pathway has also been implicated in CAPS.(65) The key to differentiating APS from vasculitis relies on the presence of persistently circulating aPL (ie, anticardiolipins, anti–b-2 glycoprotein 1 antibodies, and lupus anticoagulant), and the histologic features of the different conditions.”
BackgroundInfluentialMorales, J. M., Serrano, M., Martínez-Flores, J. A., Pérez, M. D., Castro, M. J., Sánchez, E., García, F., Rodríguez-Antolín, A., Alonso, M., Gutiérrez, E., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001199 · Cited by 29
Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
Roeser, A., Aubart, F. C., Breillat, P., Miyara, M., Emile, J., Charlotte, F., Donadieu, J., Amoura, Z., & Haroche, J. (2019) · Haematologica · doi:10.3324/haematol.2018.214007 · Cited by 27
“Interestingly, mTOR inhibitors have been proposed for ECD treatment, and were also shown efficacious in antiphospholipid syndrome.(17,18) mTOR inhibitors could probably be a good choice as a first-line treatment in patients with ECD without severe manifestation and AID when interferon-a cannot be used.”
MethodAgmon‐Levin, N., Berman, M., Harel, L., Lidar, M., Drori, T., Yahia, S. H., & Paran, D. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/cc5taf · Cited by 28
“On the other hand, various APS manifestations are linked with aPL induced inflammatory non-thrombotic effects (4).”
BackgroundRecognition and management of antiphospholipid syndrome
Gerosa, M., Meroni, P. L., & Erkan, D. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000240 · Cited by 26
ANDRADE, D. C. O. D., Cervera, R., Cohen, H., Crowther, M. A., Cuadrado, M. J., Canaud, G., Garcia, D. A., Gerosa, M., Ortel, T. L., Pengo, V., et al. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_18 · Cited by 30
Self-citationManagement of cardiovascular disease in patients with systemic lupus erythematosus
Piranavan, P., & Perl, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1770227 · Cited by 27
“Oxidiz ed LDL Liver 1 2 3 4 5 Oxidized β2GPI or Apo H Oxida"ve stress mTOR dependent Mitochondrial dysfunc"on Oxidizedβ2GPI An" β2GPI & aCL an"bodies Atherosclerosis and thrombosis Treatment will NAC will replete glutathione and maintain reduced environment mTOR blockers like rapamycin Steroids, Plasmapheresis, B cell…”
BackgroundInfluentialTreatment advances in antiphospholipid syndrome: 2022 update
Erton, Z. B., & Erkan, D. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102212 · Cited by 27
Nikolopoulos, D., Loukogiannaki, C., Sentis, G., Garantziotis, P., Manolakou, T., Kapsala, N., Nikoloudaki, M., Pieta, A., Flouda, S., Parodis, I., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-225664 · Cited by 31
“49 Treatment with sirolimus in kidney-transplant recipients with aPL showed down-regulation of mTROC pathway in intrarenal vessels which was associated with more favourable outcomes.”
BackgroundKidney retransplantation in children following rejection and recurrent disease
Graves, R. C., & Fine, R. Ν. (2016) · Pediatric Nephrology · doi:10.1007/s00467-016-3346-0 · Cited by 26
“[49] recently reported that seven of ten (70 %) recipients with APLN who were treated 2244 Pediatr Nephrol (2016) 31:2235–2247”
BackgroundPediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management
Rosina, S., Chighizola, C. B., Ravelli, A., & Cimaz, R. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-020-00976-7 · Cited by 29
Mechanisms of Cellular Activation in the Antiphospholipid Syndrome
Müller‐Calleja, N., & Lackner, K. J. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597290 · Cited by 28
Rodríguez, C. M., Velásquez, M., Rúa, C., Viana, M., Abrahams, V. M., Cadavid, Á. P., & Álvarez, Á. M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.706743 · Cited by 26
Jiang, N., Li, M., Zhang, H., Duan, X., Li, X., Fang, Y., Li, H., Yang, P., Luo, H., Wang, Y., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000617 · Cited by 25
The costimulatory receptor B7-1 is not induced in injured podocytes
Baye, E., Gallazzini, M., Delville, M., Legendre, C. M., Terzi, F., & Canaud, G. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.022 · Cited by 25
Self-citationManaging Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects
Islabão, A. G., da Trindade, V. C., da Mota, L. M. H., ANDRADE, D. C. O. D., & Silva, C. A. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00484-w · Cited by 29
“Sirolimus treatment seems to protect kidney transplants from recurrence of vascular lesions and loss of function [44] (Fig.”
BackgroundTzeng, H., & Chyuan, I. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.03.019 · Cited by 29
Difficult Clinical Situations in the Antiphospholipid Syndrome
Rosa, R. F., Lopes, M. R. U., Zeinad, A. K., D’Amico, É. A., & ANDRADE, D. C. O. D. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0502-7 · Cited by 24
Saadh, M. J., Kazemi, K., Khorramdelazad, H., Mousavi, M. J., Noroozi, N., Masoumi, M., & Karami, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110246 · Cited by 198
Ruiz‐Irastorza, G., Tektonidou, M. G., & Khamashta, M. A. (2024) · Rheumatology · doi:10.1093/rheumatology/kead538 · Cited by 25
Antiphospholipid Syndrome and Renal Allograft Thrombosis
Morales, J. M., Serrano, M., Martínez-Flores, J. A., Pérez, M. D., & Serrano, A. (2018) · Transplantation · doi:10.1097/tp.0000000000002510 · Cited by 22
Deng, X., Le, H., Wan, T., Weng, M., & Tan, Y. (2022) · Bioengineered · doi:10.1080/21655979.2022.2062969 · Cited by 21
“This suggests that the PI3K signaling members are worthy targets for developing small molecular inhibitors [30] as well as developing PI3K inhibitors to treat other autoimmune diseases, such as systemic lupus erythematosus [31], Crohn’s disease [32] and antiphospholipid syndrome [33].”
BackgroundPIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis
Yamaguchi, J., Isnard, P., Robil, N., de la Grange, P., Hoguin, C., Schmitt, A., Hummel, A., Megret, J., Goudin, N., Luka, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176402 · Cited by 23
Self-citationRodríguez‐García, M. E., Cotrina‐Vinagre, F. J., Bellusci, M., de Aragón, A. M., Hernández-Sánchez, L. C., Carnicero‐Rodríguez, P., Martín‐Hernández, E., & Martínez‐Azorín, F. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0418-1 · Cited by 22
van den Hoogen, L. L., & van Laar, J. M. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101485 · Cited by 26
Pharmacologic Complement Inhibition in Clinical Transplantation
Tatapudi, V., & Montgomery, R. A. (2017) · Current Transplantation Reports · doi:10.1007/s40472-017-0148-7 · Cited by 21
Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome
Aguirre-del-Pino, R., Monahan, R. C., Huizinga, T. W. J., Eikenboom, J. C. J., & Steup‐Beekman, G. M. (2024) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1776910 · Cited by 21
“15 In addition, a German study based on a cohort of almost 5,000 individuals described two loci (APOH and MACROD2) associated with the presence of aPL.”
Recent advances in understanding antiphospholipid syndrome
Bertolaccini, M. L., & Sanna, G. (2016) · F1000Research · doi:10.12688/f1000research.9717.1 · Cited by 24
IgA anti-β2 glycoprotein I antibodies: Experience from a large center
Vlagea, A. D., Pascual‐Salcedo, D., Doforno, R. Á., Lavilla, P., Diez, J., Padilla-Merlano, B., Cuesta‐Corral, M., & Gil, A. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.12.007 · Cited by 20
Gauthier, M., Canouï‐Poitrine, F., Guéry, E., Desvaux, D., Hüe, S., Canaud, G., Stehlé, T., Lang, P., Kofman, T., Grimbert, P., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx353 · Cited by 20
“The vascular endothelium of proliferating intra-renal vessels from patients with APS nephropathy showed indications of activation of the mTORC pathway, and kidney transplant recipients with APS nephropathy treated with sirolimus had no recurrence of vascular lesions and had decreased vascular proliferation on biopsy a…”
BackgroundResultSelf-citationInteraction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome
Feng, W., Qiao, J., Tan, Y., Liu, Q., Wang, Q., Yang, B., Yang, S., & Cui, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1361519 · Cited by 22
Towards precision medicine in antiphospholipid syndrome
López-Pedrera, C., Pérez‐Sánchez, C., & Tektonidou, M. G. (2025) · The Lancet Rheumatology · doi:10.1016/s2665-9913(25)00094-3 · Cited by 19
Hernández‐Molina, G., García-Trejo, L. P., Uribe, N., & Cabral, A. R. (2015) · PubMed · Cited by 18
Siddique, S., Risse, J., Canaud, G., & Zuily, S. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0687-z · Cited by 18
Self-citationWeaver, J. C., Krilis, S. A., & Giannakopoulos, B. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.03.048 · Cited by 19
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Laecke, S. V., Nagler, E., & Vanholder, R. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1410247 · Cited by 18
Sircana, M. C., Erre, G. L., Castagna, F., & Manetti, R. (2024) · Life · doi:10.3390/life14060716 · Cited by 20
“Such activation is associated with severe vasoconstriction in catastrophic APS syndrome [211].”
BackgroundManagement of anticoagulant-refractory thrombotic antiphospholipid syndrome
Cohen, H., Sayar, Z., Efthymiou, M., Gaspar, P., Richards, T., & Isenberg, D. A. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30116-2 · Cited by 17
Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome
Miyamae, T., & Kawabe, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061240 · Cited by 17
“The mechanistic target of rapamycin complex (mTORC) pathway has been identified to be activated in the vascular endothelium of proliferating intrarenal vessels and a putative therapeutic target in vascular lesions associated with APSN [71].”
BackgroundExosome-Contained APOH Associated With Antiphospholipid Syndrome
Tan, Y., Bian, Y., Song, Y., Zhang, Q., & Wan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.604222 · Cited by 17
“APLs, including IgG and IgM of anti-b2-glycoprotein I antibodies (also known as anti-b2-GPI; anti-APOH) and/or cardiolipin (aCL), and /or lupus anticoagulant, which have a clear correlation with the clinical manifestations of APS, but the pathophysiology between them is not clear (1, 4).”
BackgroundPathogenesis of antiphospholipid syndrome: recent insights and emerging concepts
Lackner, K. J., & Müller‐Calleja, N. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1546578 · Cited by 19
“ment with rapamycin [44] leading to protection from aPL”
BackgroundThe mTORC Pathway in the Antiphospholipid Syndrome
Eikelboom, J. W., & Weitz, J. I. (2014) · New England Journal of Medicine · doi:10.1056/nejme1406870 · Cited by 17
Cutaneous manifestations of antiphospholipid syndrome
Gómez‐Flores, M., Herrera-Argaez, G., Vázquez‐Martínez, O., Herz‐Ruelas, M. E., Ocampo‐Candiani, J., Villarreal‐Martínez, A., Galarza-Delgado, D. Á., Hernandez-Galarza, I. D. J., & Chávez‐Álvarez, S. (2021) · Lupus · doi:10.1177/0961203321990100 · Cited by 16
Mu, F., Jiang, Y., Ao, F., Wu, H., You, Q., & Chen, Z. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.084 · Cited by 16
Mora-Ramírez, M., González‐Pacheco, H., & Amezcua-Guerra, L. M. (2016) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000409 · Cited by 17
Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy
Gupta, A., Shah, U., Khine, H., Vandergriff, T. W., & Froehlich, T. W. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000335 · Cited by 16
Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells
Patsouras, M., Alexopoulou, E., Foutadakis, S., Tsiki, E., Karagianni, P., Agelopoulos, M., & Vlachoyiannopoulos, P. G. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100202 · Cited by 18
Thrombotic microangiopathies: Similar presentations, different therapies
Appel, G. B. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17001 · Cited by 15
Sevim, E., Siddique, S., Chalasani, M. L. S., Chyou, S., Shipman, W. D., O’Shea, O., Harp, J., Alpan, O., Zuily, S., Lu, T. T., et al. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.220049 · Cited by 15
Harifi, G., Nour‐Eldine, W., Noureldine, M. H. A., Berjaoui, M. B., Kallas, R., Khoury, R., Uthman, I. W., Al-Saleh, J. A., & Khamashta, M. A. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.10.016 · Cited by 17
Cole, M. A., Gerber, G. F., & Chaturvedi, S. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109828 · Cited by 14
Taghavi, M., Jabrane, A., Jacobs, L., Mesquita, M. D. C. F., Demulder, A., & Nortier, J. (2024) · Antibodies · doi:10.3390/antib13010001 · Cited by 14
“The mammalian Target of Rapamycin (mTOR) pathway, implicated in cell proliferation and survival, seems to be an important signaling pathway by which aPL trigger intimal hyperplasia and occlusive vasculopathy [6,10].”
BackgroundRichter, P., Bădescu, M. C., Rezuș, C., Ouatu, A., Dima, N., Popescu, D., Burlui, A., Bratoiu, I., Mihai, I. R., & Rezuş, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011281 · Cited by 17
“Another effect of EC activation is triggering the pathogenic cascade towards vasculopathy, through the successive involvement of phosphatidylinositol 3-kinase (PI3K)-AKT and mammalian target of rapamycin (mTOR) pathways [47].”
BackgroundJordan, N., & D’Cruz, D. P. (2015) · Arthritis Care & Research · doi:10.1002/acr.22723 · Cited by 14
“Canaud et al (24) demonstrated that treatment with sirolimus can prevent the development of these vascular lesions in renal transplant patients with aPL.”
BackgroundKidney disease in primary anti-phospholipid antibody syndrome
Gracia-Tello, B., & Isenberg, D. A. (2016) · Rheumatology · doi:10.1093/rheumatology/kew307 · Cited by 15
“These results suggest that mTORC pathway is involved in the vascular lesions associated with the antiphospholipid syndrome [26].”
BackgroundResultA importância de reconhecer a síndrome antifosfolípide na medicina vascular
Funke, A., Danowski, A., ANDRADE, D. C. O. D., Rêgo, J., & Levy, R. A. (2017) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.011416 · Cited by 26
“thrombosis with indication for moderate intensity anticoagulation (INR 2 to 3), but in whom there were difficulties achieving or maintaining the therapeutic target, VKA were substituted with 20 mg rivaroxaban per day, after which no new venous thromboembolism events were observed during follow-up with a median duratio…”
BackgroundAntiphospholipid syndrome nephropathy: Current knowledge and unanswered questions
Xourgia, E., & Tektonidou, M. G. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109735 · Cited by 13
Sciascia, S., Yazdany, J., Moroni, G. L., Becker, J. U., Seshan, S. V., Andrade, D. C. O., Emmi, G., Cuadrado, M. J., Radin, M., Cecchi, I., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.01.018 · Cited by 13
“21 Among others, a study by Canaud showed that, in vitro , aPLs can interact with the m-TOR complex, stimulating the growth and proliferation of intimal and probably endothelial cells, 22 indicating a prospect for consideration of new therapeutic options beyond anticoagulation in this setting.”
Clinical profiles and risk assessment in patients with antiphospholipid antibodies
Kato, M., Hisada, R., & Atsumi, T. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1543025 · Cited by 14
“The bindingof aPL to cells, including endothelial cells, platelets, monocytes, neutrophils, and trophoblasts, induce complement activation [17,18], tissue factor upregulation [19], platelet activation [20], neutrophil extracellular traps [21,22], and upregulation of themammalian target of rapamycin complex [23], leadi…”
BackgroundThrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment
Chighizola, C. B., & Meroni, P. L. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0741-5 · Cited by 13
Epidemiology and Management of Lupus Nephritis
Mejia-Vilet, J. M., & Rovin, B. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00059-1 · Cited by 17
Xie, W., Ji, L., & Zhang, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857424 · Cited by 12
Conti, F., Ceccarelli, F., Gigante, A., Perricone, C., Barbano, B., Massaro, L., Spinelli, F. R., Alessandri, C., Valesini, G., & Cianci, R. (2015) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2015.02.009 · Cited by 12
mTORC is a potential therapeutic target in APS
Duarte, J. H. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.141 · Cited by 12
Sartorelli, S., Luca, G. D. D., Campochiaro, C., Peretto, G., Sala, S., Esposito, A., Busnardo, E., Basso, C., Thiene, G., & Dagna, L. (2019) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2019.1574022 · Cited by 12
Baron, B. W., & Baron, J. M. (2019) · Lupus · doi:10.1177/0961203319851863 · Cited by 12
Renal and vascular outcomes in patients with isolated antiphospholipid syndrome nephropathy
Rousselin, C., Amoura, Z., Faguer, S., Bataille, P., Boffa, J., Canaud, G., Guerrot, D., Jourde‐Chiche, N., Karras, A., Auxenfants, E., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102889 · Cited by 12
Self-citationForet, T., Dufrost, V., Heymonet, M., Risse, J., Faure, G. C., Louis, H., Lagrange, J., Lacolley, P. J., Devreese, K. M. J., Gibot, S., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1926-0453 · Cited by 12
Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?
Calcaterra, I. L., Tufano, A., Lupoli, R., Iannuzzo, G., Emmi, G., & Minno, M. N. D. D. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15415 · Cited by 15
Chen, Y., Mei, X., Gan, D., Wu, Z., Cao, Y., Lin, M., Zhang, N., Yang, T., Chen, Y., & Hu, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.168 · Cited by 12
Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling
Shi, H., Liang, W., Yang, Z., Hoy, C. K., Wang, Q., Ding, Z., Pan, H., Shi, Y., Shen, Y., Sarosh, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.073552 · Cited by 11
The ABCs of antiphospholipid syndrome
Dinçer, A. B. K., & Erkan, D. (2023) · Archives of Rheumatology · doi:10.46497/archrheumatol.2023.41875 · Cited by 15
Morales, J., Serrano, M., Martínez-Flores, J. A., Gainza, F. J., Marcén, R., Arias, M., Escuín, F., Pérez, M. D., Andrés, A., Martínez, M. Á., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00468 · Cited by 11
“Only six patients did not receive calcineurin inhibitors as an initial immunosuppressive protocol, and therefore, we cannot discuss if m-TOR inhibitors can be useful in the prevention of vascular lesions associated with aPL (32).”
BackgroundSuccessful treatment of sirolimus in a Chinese patient with refractory LN and APS: a case report
Zhang, D., Sun, F., & Ye, S. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221079253 · Cited by 11
Advances in the pharmacological management of systemic lupus erythematosus
Tsoi, A., Nikolopoulos, D., & Parodis, I. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2354457 · Cited by 13
“From a clinical standpoint, kidney transplant recipients with a high-risk aPL profile who were treated with the mTORC inhibitor sirolimus exhibited a downregulation of the mTORC pathway, resulting in favorable kidney-related outcomes [91].”
BackgroundDieudonné, Y., Lorenzetti, R., Rottura, J., Janowska, I., Frenger, Q., Jacquel, L., Vollmer, O., Carbone, F., Zhu, C., Luka, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54228-8 · Cited by 13
“In renal transplant patients with APS-related nephropathy showed improved graft survival when treated with rapamycin (an mTORC1 inhibitor), which also prevented vascular lesion recurrence, such as cell proliferation and intimal hyperplasia 70 .”
Current status and future prospects for the treatment of antiphospholipid syndrome
Marzooqi, A. A., Leone, A., Saleh, J. A., & Khamashta, M. A. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1178573 · Cited by 10
REST and Stress Resistance in the Aging Kidney
Magassa, S., Aron, L., Hoguin, C., Isnard, P., Terzi, F., Legendre, C. M., Yankner, B. A., & Canaud, G. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020231 · Cited by 10
“Western Blot Western blot analysis was performed as previously described.(8) The following antibodies were used: REST (Millipore, 07–579, 1:500), b-actin (Sigma-Aldrich, A5316, 1:5000), cleaved-caspase 3 (Asp175) (5A1E) (Cell Signaling, 9664, 1:1000), poly (adp-ribose) polymerase (Cell Signaling, 9542S, 1:1000), phosp…”
Self-citationLoiseau, P., Foret, T., DeFilippis, E. M., Risse, J., Etienne, A. D., Dufrost, V., Moulinet, T., Erkan, D., Devilliers, H., Wahl, D. G., et al. (2022) · Lupus · doi:10.1177/09612033221126852 · Cited by 12
“A non-specific vascular hyperplasia is sometimes found as well as an obliterative endarteritis similar to the one described in renal lesions due to the activation of the mTOR pathway by aPL.(19,26) This highlights the existence of several mechanisms than can lead to livedo.”
BackgroundUtilizing type I interferon expression in the identification of antiphospholipid syndrome subsets
Cecchi, I., Radin, M., Rodríguez‐Carrio, J., Tambralli, A., Knight, J. S., & Sciascia, S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1901581 · Cited by 9
Yap, D. Y. H., Thong, K. M., Yung, P. S., Tang, C. S.-M., Y, B. M., & Chan, T. M. (2019) · Lupus · doi:10.1177/0961203319879990 · Cited by 11
Endosomal Redox Signaling in the Antiphospholipid Syndrome
Lackner, K. J., Manukyan, D., & Müller‐Calleja, N. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0647-7 · Cited by 9
Metadata
- Authors
- Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., Legendre, C., & Terzi, F.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 303-312
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151319957
- Cited by
- 355
- References
- 38
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 34 · 2023: 29 · 2022: 22 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 44 · 2017: 33 · 2016: 34 · 2015: 25 · 2014: 7
- FWCI
- 27.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- antiphospholipid syndrome, rapamycin, antiphospholipid antibodies, PI3K/Akt signaling, vascular endothelial cell proliferation, kidney transplantation, catastrophic antiphospholipid syndrome, renal allograft survival, vascular lesions
- MeSH terms
- Adult, Analysis of Variance, Autopsy, Endothelium, Vascular, Female, Humans, Immunoglobulin G, Immunosuppressive Agents, Kidney, Kidney Diseases, Male, Middle Aged, Kidney Transplantation, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Sirolimus, Cell Proliferation, Metabolic Networks and Pathways, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.